Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: Genotype and phenotype analyses from a case-control study

International Journal of Cancer

Volumn 126, Issue 9, 2010, Pages 2199-2210

  Zheng, Yun Ling ^a   Kosti, Ourania ^a   Loffredo, Christopher A ^a   Bowman, Elise ^b   Mechanic, Leah ^b   Perlmutter, Donna ^c   Jones, Raymond ^c   Shields, Peter G ^a   Harris, Curtis C ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle checkpoints; DNA damage; G2 M checkpoint; Genotype phenotype correlation; Lung cancer

Indexed keywords

ATM PROTEIN; BRCA2 PROTEIN; CDC25C PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA; ERCC6 PROTEIN; PROTEIN; PROTEIN P53; TP53BP1 PROTEIN; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FEMALE; GAMMA RADIATION; GENE; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; UNITED STATES; CELL DIVISION; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CASE-CONTROL STUDIES; CELL DIVISION; DNA REPAIR; FEMALE; G2 PHASE; GENES, CDC; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 77949885179     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24771     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Public Health 1987;77:425-431
3. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 2005;93:825-833
4. Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 2003;12:689-698 (Pubitemid 36993157)
5. Neumann AS, Sturgis EM, Wei Q. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog 2005;42:65-92.
6. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828
7. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989;246:629-634
8. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;23:9408-9421
9. DiPaola RS. To arrest or not to G(2)-M Cell-cycle arrest: commentary re:A. K. Tyagi et al.,Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res 2002;8:3311-3314
10. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89:7491-7495
11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311
12. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
13. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-935
14. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DA damage. Proc Natl Acad Sci USA 1993;90: 3988-3992
15. Smith GC, Divecha N, Lakin ND, Jackson SP. DNA-dependent protein kinase and related proteins. Biochem Soc Symp 1999; 64:91-104.
16. Rotman G, Shiloh Y. ATM: a mediator of multiple responses to genotoxic stress. Oncogene 1999;18:6135-6144
17. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, et al.Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999 Dec 24;286:2528-2531
18. Parshad R, Sanford KK, Jones GM. Chromosomal radiosensitivity during the G2 cell-cycle period of skin fibroblasts from individuals with familial cancer. Proc Natl Acad Sci USA 1985;82:5400-5403 (Pubitemid 15012112)
19. Knight RD, Parshad R, Price FM, Tarone RE, Sanford KK. X-ray-induced chromatid damage in relation to DNA repair and cancer incidence in family members. Int J Cancer 1993;54:589-593
20. Canman CE, Lim DS. The role of ATM in DNA damage responses and cancer. Oncogene 1998;17:3301-3308
21. Nagasawa H, Latt SA, Lalande ME, Little JB. Effects of X-irradiation on cell-cycle progression, induction of chromosomal aberrations and cell killing in ataxia telangiectasia (AT) fibroblasts. Mutat Res 1985;148:71-82.
22. Sanford KK, Parshad R, Price FM, Jones GM, Tarone RE, Eierman L, Hale P, Waldmann TA. Enhanced chromatid damage in blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene. J Natl Cancer Inst 1990;82:1050-1054
23. Taylor AM, Metcalfe JA, McConville C. Increased radiosensitivity and the basic defect in taxia telangiectasia. Int J Radiat Biol 1989;56:677-684
24. Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH, Harris CC, Montesano R, Weinstein IB. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993;90: 9026-9030
25. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000; 92:1764-1772
26. Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 2002;29:246-257
27. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000;33:261-274
28. Zheng YL, Loffredo CA, Alberg AJ, Yu Z, Jones RT, Perlmutter D, Enewold L, Krasna MJ, Yung R, Shields PG, Harris CC. Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans. Cancer Res 2005;65:9566-9573
29. Xing J, Spitz MR, Lu C, Zhao H, Yang H, Wang W, Stewart DJ, Wu X. Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2007;16:1517-1522
30. Zheng YL, Loffredo CA, Yu Z, Jones RT, Krasna MJ, Alberg AJ, Yung R, Perlmutter D, Enewold L, Harris CC, Shields PG. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: Acase-control study with population and hospital controls. Carcinogenesis 2003;24:269-274
31. Morin PA, Saiz R, Monjazeb A. High-throughput single nucleotide polymorphism genotyping by fluorescent 5 exonuclease assay. Biotechniques 1999;27: 538-40, 542, 544.
32. Matakidou A, el GR, Webb EL, Rudd MF, Bridle H, Eisen T, Houlston RS. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 2007;16:2333-2340
33. Ries L, Melbert D, Krapcho M.SEER cancer statistics review, 1975-2004.Bethesda, MD:National Cancer Institute;2006.
34. Pinsky PF. Racial and ethnic differences in lung cancer incidence: how much is explained by differences in smoking patterns? (United States). Cancer Causes Control 2006;17:1017-1024
35. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le ML. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006;354:333-342
36. Risch N. Dissecting racial and ethnic differences. N Engl J Med 2006;354:408-411
37. Weber WW. Populations and genetic polymorphisms. Mol Diagn 1999;4:299-307.
38. Garte S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998; 19:1329-1332
39. Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 2000;18:2309-2315
40. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P, III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 2002;94:108-115
41. Nakajima M, Yokoi T. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 2005;20:227-235
42. Duell EJ, Millikan RC, Pittman GS, Winkel S, Lunn RM, Tse CK, Eaton A, Mohrenweiser HW, Newman B, Bell DA. Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev 2001;10:217-222
43. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, et al.Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391
44. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst 2002;94: 681-690
45. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF. Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58:65-70.
46. Tang YM, Green BL, Chen GF, Thompson PA, Lang NP, Shinde A, Lin DX, Tan W, Lyn-Cook BD, Hammons GJ, Kadlubar FF. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000;10: 761-766
47. Mechanic LE, Bowman ED, Welsh JA, Khan MA, Hagiwara N, Enewold L, Shields PG, Burdette L, Chanock S, Harris CC. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 2007;16:214-222
48. Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell 1997;88: 315-321
49. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11: 1513-1530
50. Zhao H, Wang LE, Li D, Chamberlain RM, Sturgis EM, Wei Q. Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis. Carcinogenesis 2008;29: 1560-1566
51. Lin J, Swan GE, Shields PG, Benowitz NL, Gu J, Amos CI, de AM, Spitz MR, Wu X. Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation. Cancer Epidemiol Biomarkers Prev 2007;16: 2065-2071